Contract 75A50119C00037
Emergent Biosolutions Canada Inc · Department Of Health And Human Services · May 31, 2019
Emergent Biosolutions Canada Inc was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on May 31, 2019 for $422.32 million of work in pharmaceutical preparation manufacturing. It was awarded under full and open competition. The contract has been modified 17 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on March 23, 2026. If all options are exercised, the contract could reach $706.47 million.
Contract details
- PIID
- 75A50119C00037
- Award type
- Definitive Contract
- Pricing
- Firm Fixed Price
- Set-aside
- No Set Aside Used.
- Competition
- Not Competed
- NAICS
- 325412 · Pharmaceutical Preparation Manufacturing
- Product / service
- Drugs And Biologicals
- First action
- May 31, 2019
- Latest action
- March 23, 2026
Description
VACCINIA IMMUNE GLOBULIN INTRAVENOUS (VIG-IV) BUY AND ASSOCIATES SERVICES FOR UP TO 10 YEARS.
Modification timeline
-
March 23, 2026Mod P00017$53.73M
-
July 2, 2025Mod P00016$51.92M
-
June 30, 2025Mod P00015VACCINIA IMMUNE GLOBULIN INTRAVENOUS (VIG-IV) BUY AND ASSOCIATED SERVICES FOR UP TO 10 YEARS.$0
-
June 13, 2025Mod P00014VACCINIA IMMUNE GLOBULIN INTRAVENOUS (VIG-IV) BUY AND ASSOCIATED SERVICES FOR UP TO 10 YEARS.$0
-
June 2, 2025Mod P00013VACCINIA IMMUNE GLOBULIN INTRAVENOUS (VIG-IV) BUY AND ASSOCIATED SERVICES FOR UP TO 10 YEARS.$0
-
March 4, 2025Mod P00012VACCINIA IMMUNE GLOBULIN INTRAVENOUS (VIG-IV) BUY AND ASSOCIATED SERVICES FOR UP TO 10 YEARS.$0
-
June 10, 2024Mod P00011VACCINIA IMMUNE GLOBULIN INTRAVENOUS (VIG-IV) BUY AND ASSOCIATED SERVICES FOR UP TO 10 YEARS.$62.70M
-
February 22, 2024Mod P00010VACCINIA IMMUNE GLOBULIN INTRAVENOUS (VIG-IV) BUY AND ASSOCIATED SERVICES FOR UP TO 10 YEARS.$0
-
May 19, 2023Mod P00009EXTENSION OF ORDERING PERIOD FOR OPTION 5/YEAR 5 TO 5/30/2023.$60.58M
-
March 20, 2023Mod P00008EXTENSION OF ORDERING PERIOD FOR OPTION 5/YEAR 5 TO 5/30/2023.$0
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Four Points Technology, L.L.C. | Department Of Health And Human Services | March 31, 2026 | $246.6K |
| Astrazeneca Pharmaceuticals Lp | Department Of Health And Human Services | March 31, 2026 | $122.8K |
| Ase Direct, Inc. | Department Of Health And Human Services | March 30, 2026 | $49.0K |
| Mckesson Corporation | Department Of Health And Human Services | March 30, 2026 | $9.00M |
| Emergent Biosolutions Canada Inc | Department Of Health And Human Services | March 30, 2026 | $256.40M |
| Sanofi Vaccines Us Inc. | Department Of Health And Human Services | March 27, 2026 | $92.33M |
Top contractors in NAICS 325412
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Mckesson Corporation | 53,729 | $99.76B |
| 2 | Pfizer Inc | 4,613 | $28.68B |
| 3 | Merck Sharp & Dohme Llc | 391 | $21.58B |
| 4 | Modernatx, Inc. | 3 | $8.20B |
| 5 | Sanofi Vaccines Us Inc. | 5,248 | $7.76B |
| 6 | Glaxosmithkline, Llc | 1,418 | $7.22B |
| 7 | Merck Sharp & Dohme Corp. | 349 | $5.33B |
| 8 | Pfizer Inc. | 3,842 | $4.83B |
| 9 | Eli Lilly And Company | 18 | $4.67B |
| 10 | Amerisourcebergen Drug Corp | 497 | $3.23B |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75A50119C00037?
Contract 75A50119C00037 is a federal contract awarded to Emergent Biosolutions Canada Inc by Department Of Health And Human Services on May 31, 2019 for $422.32 million of work classified under PHARMACEUTICAL PREPARATION MANUFACTURING. It has been modified 17 times since the base award.
Who won contract 75A50119C00037?
Emergent Biosolutions Canada Inc won contract 75A50119C00037 from Department Of Health And Human Services.
How much is contract 75A50119C00037 worth?
Contract 75A50119C00037 has obligated $422.32 million to date, with a total potential value of $706.47 million if all options are exercised.